Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes Society
LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders,…
Read this Press Release: Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes SocietyPoxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes
Imeglimin Phase 3 trial (TIMES 1) met its primary and main secondary endpoints Imeglimin Phase 3 TIMES 3 16-week, double-blind, placebo controlled, randomized part…
Read this Press Release: Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 DiabetesPoxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial
PXL065 observed to have a favorable safety, tolerability and pharmacokinetic profile in the Phase 1a trial PXL065 is advancing into a Phase 1b multiple ascending dose…
Read this Press Release: Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial
